Search global stocks & ETFs...Ctrl K
Learn Mode
TEM logo

TEM - Tempus AI Inc

103


$46.23

-$0.26 (-0.559%)
5/22/26, 2:50 PM
General
Scores
Financials & KPIs
Dividends
Analyst
Insider
TEM
Valuation Score
View as %

Stock Unlock Logo
Stock Unlock
$42$104MayJulSepNovJanMar

1D
1W
1M
YTD
1Y
3Y
5Y
Max

Stock Profile
  • Market Cap
    $8.53B
  • Industry
    Life Sciences Tools & Services
  • EPS (TTM)
    -$1.69
  • P/E (TTM)
    0.00
  • Div & Yield
    --
  • FCF Payout Ratio
    --
  • P/S (TTM)
    6.26
  • P/B
    20.49
  • Diluted Shares
    178.88M
  • Ex-Dividend
    --
  • Next Earnings
    07-31
  • Forward P/E
    0.00
  • Payout Ratio
    --
  • P/FCF (TTM)
    0.00
  • FCF Yield
    --
  • Earnings Yield
    -3.55%
  • 52 Week Range
--
Tempus AI Inc has a current cash runway of 34.91 months. The cash runway is the amount of time the business has at its current burn rate before it will need to take on debt or dilute shareholders to raise more money. However, it has grown revenue at 69.82% over the past year, which is strong growth.
Valuation Model
Key Score
--
--
Management
2.00
Bad

Growth
4.00
Good

Profitability
5.00
Very Good
Fin. Health
5.00
Very Good

Dividends
--
--

Analyst
2.00
Bad
Insider Transactions
Explore Insider Tab
Buy
Sell
202420252026$0$200M$400M$600M$800M
Market News
Page 1 of 21
Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-21 17:05:16


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-21 17:05:13


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-21 17:05:12


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-21 17:05:10


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-21 17:05:07


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-21 17:05:05


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-15 17:03:15


Form 8-K
Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-12 19:18:38


Form SCHEDULE 13G/A
Unknown Form Type

Filed on 2026-05-07 10:05:25


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-06 16:30:23


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-06 16:30:19


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-06 16:30:17

Page 1 of 21
Revenue
Earnings
Free Cash Flow
2022202320242025-$1.30B-$650M$0$650M$1.30B
Price Targets
Go to Analyst Tab
These are one year price targets for: 2027-05-11
High:
$105.00
127.1%
Avg:
$72.38
56.6%
Low:
$35.35
-23.5%
(% change is relative to the current stock price: $46.23)
Analyst Recommendations
Go to Analyst Tab
3.79
Good
25%
Strong Buy (6)
38%
Buy (9)
33%
Hold (8)
0%
Sell (0)
4%
Strong Sell (1)
About
Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. The company is headquartered in Chicago, Illinois and currently employs 3,800 full-time employees. The company went IPO on 2025-05-30. The company offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. The company provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
  • IPO Date
    2025-05-30
  • Industry
    Life Sciences Tools & Services
  • Total Employees
    3,800
  • Exchange
    Nasdaq Nms - Global Market
  • Reporting Currency
    USD
  • GICS
    Life Sciences Tools & Services
  • GICS Sub
    Life Sciences Tools & Services
  • GICS Sector
    Health Care
  • GICS Group
    Pharmaceuticals, Biotechnology & Life Sciences